Truncated MeCP2 Polypeptides for Rett Syndrome Therapy Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Rett syndrome, a neurological disorder caused by reduced MeCP2 activity, are not specific and primarily focus on managing symptoms, lacking a means to treat or prevent the disorder effectively.
Innovation Solution
Development of synthetic polypeptides comprising MBD and NID domains with at least 70% similarity to MeCP2 sequences, potentially with deletions or substitutions, and encoded by nucleic acid constructs, expression vectors, or delivered via virions, to address the key functions of MeCP2 in treating or preventing Rett syndrome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional non-specific treatments are used for Rett syndrome, then symptom management is provided, but treatment effectiveness and specificity are insufficient
Solution Approach 1:
The MeCP2 protein is segmented into its essential functional domains (MBD and NID) to create a truncated synthetic polypeptide. This segmentation retains the core therapeutic function of MeCP2 binding to methylated DNA and recruiting co-repressors while eliminating non-essential regions, thereby improving treatment effectiveness without excessive complexity
Solution Approach 2:
The essential MBD and NID domains are extracted from the full-length MeCP2 protein to create a minimal functional unit. This extraction provides a simplified therapeutic agent that delivers the specific MeCP2 function needed for treating Rett syndrome, improving both effectiveness and specificity
2Reliability
If full-length MeCP2 protein is used for therapy, then complete MeCP2 function is provided, but delivery efficiency and safety are reduced
Solution Approach 1:
Non-essential portions of the MeCP2 protein are removed to create a truncated synthetic polypeptide containing only the critical MBD and NID domains. This reduction in protein size and complexity improves delivery efficiency and reduces the risk of toxicity while preserving the essential therapeutic function of binding methylated DNA and recruiting co-repressor complexes
Solution Approach 2:
The protein structure is modified by changing its size and domain composition parameters. The truncated polypeptide maintains the critical functional parameters (MBD for DNA binding, NID for co-repressor recruitment) while altering non-critical parameters, thereby improving safety and delivery without sacrificing therapeutic efficacy
3Object-affected harmful factors
If synthetic polypeptides with deleted regions are used, then delivery and safety are improved, but structural completeness is reduced
Solution Approach 1:
The MeCP2 protein is strategically segmented to retain only the stable and essential MBD and NID domains. This segmentation creates a truncated polypeptide with improved stability for therapeutic use, as the retained domains are structurally stable and functionally critical, while eliminating regions that could contribute to instability or toxicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The synthetic polypeptides provide targeted treatment with reduced toxicity and improved delivery, offering safer and more effective methods for treating or preventing Rett syndrome by mimicking essential MeCP2 functions.
Implementation Method 1
MeCP2 is an abundant mammalian protein that selectively binds 5-methyl cytosine residues in symmetrically methylated mCpG dinucleotides
Implementation Method 2
the NCoR/SMRT Interaction Domain (NID)... MeCP2 has been implicated in several cellular processes based on its reported interaction with >40 binding partners including transcriptional co-repressors
Data Source
AI summary
MeCP2 based therapy. The present invention relates to synthetic polypeptides that are useful in the treatment of disorders associated with reduced MeCP2 activity, including Rett syndrome. The present invention provides synthetic polypeptides comprising: i) an MBD amino acid sequence showing at least 70% similarity with the amino acid sequence as depicted in SEQ ID NO: 1; and ii) an NID amino acid sequence showing at least 70% similarity with the amino acid sequence as depicted in SEQ ID NO: 2, wherein the polypeptide has a deletion of at least 50 amino acids, when compared to the full length MeCP2 e1 and e2 sequences. The invention further provides nucleic acid constructs, expression vectors, virions, pharmaceutical compositions, and cells providing polynucleotides of the invention. The invention further provides methods of treating or preventing disease in an animal comprising administering to said animal a synthetic polypeptide according to the invention.